Dr. Stephenson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1055 N 300 W
Ste 401
Provo, UT 84604Phone+1 801-357-7499Fax+1 801-373-5980
Summary
- Dr. Ryan Stephenson is an Otolaryngologist - Head and Neck Surgeon and Laryngologist in Provo, UT and is affiliated with PEAK ENT Associates. He received his medical degree from University of Pittsburgh School of Medicine and completed residency and fellowship at UCLA Department of Head and Neck Surgery. He specializes in laryngology & voice disorders and is experienced in swallowing disorders, nasal and sinus surgery, endocrine surgery, and otolaryngic allergy.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Laryngology, Voice Disorders, & Bronchoesophagology, 2019 - 2020- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Otolaryngology - Head and Neck Surgery, 2014 - 2019
University of Pittsburgh School of MedicineClass of 2014
Certifications & Licensure
UT State Medical License 2020 - 2026
CA State Medical License 2016 - 2022- American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
Publications & Presentations
PubMed
- 7 citationsImmunohistochemical location of Na+, K+-ATPase α1 subunit in the human inner ear.Ryan Stephenson, Astkhik Mangasarian, Gail Ishiyama, Kumiko Hosokawa, Seiji Hosokawa
Hearing Research. 2021-02-01 - 38 citationsTLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR + head and neck cancer cellsChwee Ming Lim, Ryan M. Stephenson, Andres M. Salazar, Robert L. Ferris
Oncoimmunology. 2013-06-01 - 60 citationsTLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.Ryan M. Stephenson, Chwee Ming Lim, Maura Matthews, Gregory N. Dietsch, Robert M. Hershberg
Cancer Immunology, Immunotherapy. 2013-05-18
Journal Articles
- The role of toll-like receptor (TLR) agonists in combinational immunotherapy for head and neck cancerB. Kansy, Y. Lei, J. Li, R.M. Srivastava, R. Stephenson, S. Brandau, S. Lang, R.L. Ferris, Oral Oncology, 3/29/2015
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
